July is Sarcoma Awareness Month, a time dedicated to bringing attention to one of oncology’s most complex and underrecognized diagnoses. Sarcomas are cancers of the connective tissues — bone, cartilage, muscle, fat, nerves, and blood vessels — and they account for approximately 1% of adult cancers and 15% of cancers in children. Their rarity means many patients are initially seen by clinicians who have limited experience with these tumors, making early specialist referral and access to advanced treatment technology critically important.
Among the treatment options available for sarcoma, proton therapy has earned a particularly strong evidence base — especially for tumors that arise near the skull base, spine, and sacrum, where surgical resection is often incomplete and conventional radiation faces significant dose constraints.
The Sarcomas Where Proton Therapy Has the Strongest Role
Chordoma
Chordoma is a rare, slow-growing malignant tumor that arises from remnants of the notochord, the embryonic structure that gives rise to the spine. The most common sites are the sacrum (the base of the spine) and the clivus (the skull base). Because of their location — intimately associated with the brainstem, spinal cord, and cranial nerves — chordomas present a radiation planning challenge that conventional X-ray therapy struggles to meet. Proton therapy is now considered the standard of care for unresectable or incompletely resected chordoma, with published series demonstrating 5-year local control rates of 60-80% in skull base and 50-70% in sacral disease.
Chondrosarcoma
Chondrosarcoma of the skull base and axial skeleton behaves similarly to chordoma from a radiation planning perspective. These tumors require high doses — often 70-74 Gy — to achieve meaningful local control, doses that cannot be safely delivered with conventional photon radiation without unacceptable risk to adjacent neural structures. Proton therapy’s ability to deliver the required dose while protecting the brainstem, optic apparatus, and temporal lobes makes it the preferred modality for this indication at experienced centers worldwide.
Ewing Sarcoma
Ewing sarcoma, primarily a disease of children and young adults, often requires radiation as part of definitive local control — either as primary treatment for unresectable disease or as adjuvant therapy following surgery. Given that many Ewing sarcoma patients are teenagers or young adults, the long-term consequences of radiation exposure to surrounding bone, soft tissue, and organs are particularly significant. Proton therapy’s dosimetric advantages — reducing scatter dose to the growing skeleton and adjacent organs — have made it an increasingly preferred approach for Ewing sarcoma cases that require radiotherapy.
Understanding the Dosimetric Advantage
The core advantage of proton therapy for sarcoma comes down to dose conformality. Protons deposit their energy at a defined depth (the Bragg Peak) and stop, rather than continuing to irradiate tissue beyond the tumor as X-rays do. For tumors wrapped around the spinal cord or adjacent to the brainstem, this physics difference is clinically decisive: it means the radiation oncologist can prescribe a tumoricidal dose without exceeding tolerance limits for the adjacent neural structures.
At Tennessee Oncology Proton Center, we use Pencil Beam Scanning (PBS) technology, which adds another layer of precision by allowing the proton beam to be painted across the target volume in three dimensions, conforming tightly to irregular tumor shapes that are common in sarcoma.
The Multidisciplinary Approach to Sarcoma Care
Sarcoma treatment is rarely the province of a single specialist. Optimal outcomes depend on close coordination among orthopedic oncologists, medical oncologists, radiation oncologists, pathologists with sarcoma expertise, and reconstructive surgeons. The Sarcoma Foundation of America consistently emphasizes that patients with sarcoma should be treated at high-volume centers with multidisciplinary expertise.
As part of the Tennessee Oncology network, Tennessee Oncology Proton Center can facilitate referrals and coordination with surgical and medical oncology colleagues. Our radiation oncology team reviews complex sarcoma cases in a multidisciplinary setting to ensure that proton therapy is integrated thoughtfully into the broader treatment plan.
Seeking a Second Opinion This Sarcoma Awareness Month
Because sarcomas are rare and treatment decisions are complex, second opinions at specialized centers are not just acceptable — they are encouraged. If you or a loved one has been diagnosed with a bone or soft tissue sarcoma, particularly one involving the spine, sacrum, skull base, or pelvis, we encourage you to reach out to our team for a consultation.
Proton therapy is not the right answer for every sarcoma patient, but for those with tumors in locations where dose constraints make conventional radiation inadequate, it can make the difference between a treatable and an untreatable disease. Contact Tennessee Oncology Proton Center to discuss whether proton therapy should be part of your sarcoma treatment plan.
